# Harnessing the biophysics of multivalent nanoparticle adhesion to control cell targeting and internalization

> **NIH NIH R21** · UNIVERSITY OF CALIFORNIA-IRVINE · 2020 · $224,790

## Abstract

ABSTRACT
 Targeted delivery of nanocarrier contrast and drug delivery agents holds exciting potential
for treating major human diseases, but new strategies are needed to maximize targeting efficiency
and selectivity. A powerful attribute of nanoparticles is the ability to form multiple bonds with target
cells, thereby enhancing overall adhesion strength and internalization rate. However, we currently
know little about the factors that govern multivalent nanoparticle binding at the molecular level.
Addressing this limitation would dramatically impact the field of targeted delivery and enable
unprecedented control over multivalent nanoparticle adhesion. One of the biggest challenges is
controlling targeting selectivity between normal and diseased cells that express the target molecule
at different levels. Ideally the nanoparticle would display superselectivity, such that a switch-like
change in binding efficiency is observed between normal and diseased cells. To date,
superselectivity has only been observed in a computational model, but experimental demonstration
remains a major goal in the targeting field. In previous work, we developed novel experimental
methods for assessing multivalent nanoparticle adhesion dynamics and a computational simulation
called Nano Adhesive Dynamics (NAD) that we used to uncover new information about bond
number, dynamics, and forces. In this proposal, we will transform our experimental and simulation
tools into a versatile and robust design platform that could be used to control nanoparticle binding
to, and internalization within, live cells. We will use vascular inflammation, specifically the target
ICAM-1, as a model system for this work due to our past experience, large inventory of affinity
molecules in published literature, and connection to major diseases. Furthermore, previous work
has already established the need for superselective targeting of ICAM-1. We will first add new
capabilities to NAD simulations, including incorporation of the initial attachment of nanoparticles
from free solution and extension of the methods to nanorods. The second phase will focus on
testing molecular bond properties, with new flow chamber experiments performed using a diverse
panel of anti-ICAM-1 adhesion molecules with different bond properties, as well as a class of
springy peptide linkers that we hypothesize will act as molecular springs that reduce mechanical
forces. The final phase of the project will be focused on adapting the work to the context of live
endothelial cells, and using the NAD simulations to design and test prospective affinity molecule-
nanoparticle formulations that exhibit superselective targeting behavior to normal and inflamed
endothelium. The Specific Aims include: (1) advance the NAD simulation framework to model initial
attachment and nanorods, (2) evaluate new molecular bond properties, (3) assess multivalent
adhesion to endothelial cells, and (4) design a nanocarrier that displays superselectivity. A...

## Key facts

- **NIH application ID:** 9888996
- **Project number:** 1R21EB027883-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Jered Brackston Haun
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $224,790
- **Award type:** 1
- **Project period:** 2020-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9888996

## Citation

> US National Institutes of Health, RePORTER application 9888996, Harnessing the biophysics of multivalent nanoparticle adhesion to control cell targeting and internalization (1R21EB027883-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/9888996. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
